Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Sage Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Sage Therapeutics, Inc.

SAGE

Sage Therapeutics, Inc.

About Sage Therapeutics, Inc.

Sage Therapeutics is a biopharmaceutical company focused on developing brain health medicines targeting CNS receptor systems, primarily GABA and NMDA. Its core product, ZURZUVAE, is an FDA-approved oral treatment for postpartum depression. The company advances novel compounds for neuropsychiatric and neurodevelopmental disorders, leveraging proprietary chemistry and strategic collaborations to develop and commercialize therapies that improve brain function and patient outcomes.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Sage Therapeutics, Inc.

1
1
Sage Therapeutics, Inc. Sage Therapeutics Reports $31.7M Revenue and $49.7M Net Loss for Q2 2025

Via official filing (AI summary) | 11 months ago | 0 comments

2
1
Sage Therapeutics, Inc. Sage Therapeutics Reports $14.1 Million Revenue in Q1 2025, Focuses on ZURZUVAE Commercialization

Via official filing (AI summary) | about 1 year ago | 0 comments

3
1
Sage Therapeutics, Inc. Sage Therapeutics Reports $400.6M Net Loss for 2024, Sees Revenue Decrease

Via official filing (AI summary) | over 1 year ago | 0 comments

4
1
Sage Therapeutics, Inc. Sage Therapeutics Reports Significant Revenue Growth, Net Loss Improvement in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments